Dr. Richard Pratley, Medical Director at AdventHealth Diabetes Institute
Publisher |
Becker's Healthcare
Media Type |
audio
Publication Date |
Jun 25, 2024
Episode Duration |
00:07:22

In this episode, Dr. Richard Pratley, Medical Director at AdventHealth Diabetes Institute, discusses a groundbreaking study on Ozempic. Dr. Pratley shares insights from the global FLOW study, highlighting Ozempic's potential to reduce chronic kidney disease progression, cardiovascular events, and overall mortality in high-risk patients with type 2 diabetes.

This episode currently has no reviews.

Submit Review
This episode could use a review!

This episode could use a review! Have anything to say about it? Share your thoughts using the button below.

Submit Review